ArticleCancers2020
Beyond the Influence of
Article in Cancers, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed, 35 citations in OpenAlex.
- Chondrosarcoma: A comprehensive review of tumor biology, clinical behavior, and therapeutic advances.Cancer treatment reviews · 2026Review
- Drug Screening of Sarcoma Cells: Finding Shared Sensitivities.Cancer research communications · 2026Article
- Malignant Transformation of Musculoskeletal Lesions with Imaging-Pathology Correlation-Part 1: Bone Lesions.Diagnostics (Basel, Switzerland) · 2025Review
- BCOR-Mutated Conventional and Dedifferentiated Chondrosarcoma: A Clinicopathologic Study.Genes, chromosomes & cancer · 2025Article
- Advances in the Molecular Biology of Chondrosarcoma for Drug Discovery and Precision Medicine.Cancers · 2025Review
- Establishment and characterization of TK-DDCS1: a novel IDH1 mutated dedifferentiated chondrosarcoma cell line.Human cell · 2025Article
- Neomorphic IDH Heterodimer Mutants: An Underestimated Point in Cancer Pathogenesis.Current cancer drug targets · 2025Review
- Establishment and characterization of a novel patient-derived cell line from conventional central grade 3 chondrosarcoma, NCC-CS1-C1.Human cell · 2024Article
- Genetics and Molecular Pathogenesis of the Chondrosarcoma: A Review of the Literature.Current issues in molecular biology · 2024Review
- Targeting Isocitrate Dehydrogenase (IDH) in Solid Tumors: Current Evidence and Future Perspectives.Cancers · 2024Review
- Advancing the Management of Skull Base Chondrosarcomas: A Systematic Review of Targeted Therapies.Journal of personalized medicine · 2024Review
- Diagnostics ofDiagnostics (Basel, Switzerland) · 2024Article
- Article
- IDH mutations in G2-3 conventional central bone chondrosarcoma: a mono institutional experience.BMC cancer · 2023Article
- Dedifferentiated Chondrosarcoma from Molecular Pathology to Current Treatment and Clinical Trials.Cancers · 2023Review
- Review
- Epigenetic Abnormalities in Chondrosarcoma.International journal of molecular sciences · 2023Review
- Biology and Management of High-Grade Chondrosarcoma: An Update on Targets and Treatment Options.International journal of molecular sciences · 2023Review
- Can We Efficiently Target HDAC in Cancer?Cancers · 2022Article
- Growth Inhibition and Induction of Innate Immune Signaling of Chondrosarcomas with Epigenetic Inhibitors.Molecular cancer therapeutics · 2021Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 3 institutions in 1 country.
Funding
Abstract
Mutations in the isocitrate dehydrogenase (
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.